Contineum Therapeutics (CTNM) vs Bright Minds Biosciences (DRUG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Contineum Therapeutics (CTNM) has outperformed Bright Minds Biosciences (DRUG) over the past year, gaining 10.0% versus a loss of 12.0%. Bright Minds Biosciences is the larger company by market cap ($533.2 million vs $503.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTNM | DRUG |
|---|---|---|
| Share price | $13.38 | $54.05 |
| Market cap | $503.37M | $533.15M |
| 1-day change | +1.52% | +3.94% |
| YTD return | +17.06% | -30.74% |
| 1-year return | +10.03% | -11.99% |
| 5-year return | — | +45.49% |
| EPS (TTM) | $-1.73 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.79 | $123.75 |
| 52-week low | $8.60 | $47.23 |
| Distance from 52-week high | -24.77% | -56.32% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +67.64% | +181.17% |
| Average volume | 526.32K | 155.37K |
| Shares outstanding | 32.96M | 9.86M |
| Employees | 51 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTNM has outperformed DRUG by 22.0 percentage points over the past year.
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
CTNM vs DRUG FAQ
Which is bigger, Contineum Therapeutics or Bright Minds Biosciences?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $533.15M compared with $503.37M for Contineum Therapeutics (CTNM).
Which stock has performed better over the past year, CTNM or DRUG?
CTNM returned +10.03% over the past 12 months, compared with -11.99% for DRUG (price return, excluding dividends). Past performance does not predict future results.
Are Contineum Therapeutics and Bright Minds Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.